by John Conrad | Jan 19, 2023 | Member News
As Horizon ties up the loose ends for its $28 billion sale to Amgen, a drug it picked up from a previous acquisition of its own is delivering a mid-stage win. Horizon had already declared Phase II success for dazodalibep among one group of patients with Sjögren’s...